Last reviewed · How we verify

NCT04169256

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers

Completed Phase 1 Last updated 4 February 2021
What this trial tests

Phase 1 trial testing HYR-PB21 in Acute Postoperative Pain in 32 participants. Completed in 30 July 2020.

Timeline
3 March 2020
Primary endpoint
30 July 2020
30 July 2020

Quick facts

Lead sponsorFruithy Medical Pty Ltd
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment32
Start date3 March 2020
Primary completion30 July 2020
Estimated completion30 July 2020
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Fruithy Medical Pty Ltd — full company profile →

Who can join

Adults 18 to 50, any sex, with Acute Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is the first time into human study (FTIH) for HYR-PB21 for injection. The study will evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending and single subcutaneous dose of HYR-PB21 for injection in healthy adult volunteers.The results of this study are intended to be used to identify appropriate and well tolerated doses of HYR-PB21 for injection to be used in further studies. A comparison of PK/PD characteristics between HYR-PB21 for injection and EXPAREL will also be included in this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Postoperative Pain

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04169256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing